Mwandishi:
Mhariri:
Imeboreshwa;
ULY CLINIC
ULY CLINIC
27 Oktoba 2026, 13:25:33
Sickle cell disease: newborn screening and early infant diagnosis
Sickle cell disease: newborn screening and early infant diagnosis
Chanzo: National Sickle Cell Disease Management Guidelines, Ministry of Health Tanzania. Toleo: 2nd edition, June 2026. Mwongozo wa Taifa (supporting guideline).
Why early infant diagnosis matters
Prompt life-saving care: penicillin prophylaxis (prevents fatal infections such as pneumococcal sepsis), folic acid, and hydroxyurea (reduces pain crises, transfusions and admissions).
Fewer life-threatening complications: timely pneumococcal and meningococcal vaccines; fewer severe infections, strokes, acute chest syndrome, splenic sequestration and early deaths.
Continuous care: diagnosed infants are enrolled in SCD clinics for follow-up, growth monitoring, education and psychosocial support.
Family awareness and genetic counselling about the genetic nature of SCD, risks for future pregnancies and early care.
Better survival: countries with newborn screening (e.g. the USA) reduced childhood SCD mortality by over 70%; pilots in Kigoma and Tabora are expected to give Tanzania a model to scale up.
Early infant diagnosis workflow (within RCH services)
1. Who and when to screen
Target population: newborns in the labour ward; all infants attending RCH clinics; siblings under 5 years of children with SCD; all children under 5 with unknown SCD status attending RCH.
Timing: preferably at birth (before discharge from maternity), or at the first immunisation visit.
2. Consent and education
Obtain verbal informed consent from the parent or guardian (written consent is not required).
Explain the purpose of screening, the possible results (SCD, sickle cell trait, normal) and the follow-up plan for each result.
Education ideally begins at antenatal visits to improve awareness and acceptance.
3. Data and sample collection
Record the infant's name, date of birth, sex, location and caregiver contacts (3 phone numbers if possible).
Collect the sample by heel prick in newborns, or finger prick or venepuncture in older infants.
Label the testing device with the child's name or ID, the date of sample collection and the time between testing and reading the result.
4. Screening test
Use an approved point-of-care test (POCT) such as Sickle SCAN®, HemoTypeSC™ or Gazelle™, following the manufacturer's instructions and the SOP.
5. Recording and interpreting results
Record the result and the time of reporting in the screening register and on the RCH card.
Table 1. Interpretation of sickle cell screening results (national guideline)
Result | Meaning |
HbAA | Normal |
HbAS or HbAC | Sickle cell trait |
HbSS or HbSC | Sickle cell disease |
In infants, repeat the POCT on the same spot to confirm an HbSS or HbSC result; early screening can give unclear results because of high fetal haemoglobin.
HbAS or HbAC with a blood transfusion in the past 3 months: repeat the test 3 months after the last transfusion.
Invalid result (no control line): record it in the register and repeat with a new strip or cassette; do not give the client an invalid result.
HbAS result with symptoms suggesting SCD: refer for haemoglobin quantification by electrophoresis or HPLC to rule out sickle beta-thalassaemia.
6. Inconclusive (intermediate) results
Repeat the test with a new blood sample.
If still inconclusive, refer the infant or send the sample for confirmatory testing by HPLC, isoelectric focusing (IEF) or Hb electrophoresis, at district/regional hospitals and above, referral laboratories or specialised SCD clinics.
7. Communicating results
Share the result directly with the parent or caregiver, with a clear explanation of what it means.
Issue an SCD health passport to every confirmed SCD patient for continuity of care.
8. Counselling and referral
Table 2. Action by screening result (national guideline)
Result | Action |
HbSS or HbSC (SCD) | Genetic counselling; link immediately to the SCD/paediatric/NCD clinic; baseline investigations (safety, eligibility, reference for monitoring); comprehensive care (prophylactic antibiotics, folic acid, immunisations, early management of complications); start hydroxyurea according to the eligibility criteria (from 9 months). |
HbAS or HbAC (trait) | Genetic counselling; educate the family about what the trait means and the chances of inheritance; counsel that the child may pass the trait to the next generation; test other siblings. |
HbAA (normal) | Give the result to the mother/caregiver and reassure them that the child does not carry a sickle cell gene. |
Follow-up of infants with SCD: monitor the baby's Hb; complete all other vaccines as scheduled; hydroxyurea from 9 months of age; penicillin V prophylaxis; screen all infants of mothers with SCD and all siblings of infants with SCD.
Imeandikwa:
27 Oktoba 2026, 13:23:58
Rejea za mada:
1. Ministry of Health Tanzania. National Sickle Cell Disease Management Guidelines, 2nd edition. June 2026. Part IV, section 11: Newborn screening and early infant diagnosis, including the SOP for maternal and early infant screening (pages 35–40).
